Alexion Pharmaceuticals has patented a method for viral filtration of fluids containing recombinant antibodies. The process involves adjusting pH, adding stabilizing agents, and using specific filters to produce a filtrate. This innovation enhances the manufacturing of recombinant antibodies. GlobalData’s report on Alexion Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Alexion Pharmaceuticals, was a key innovation area identified from patents. Alexion Pharmaceuticals's grant share as of February 2024 was 70%. Grant share is based on the ratio of number of grants to total number of patents.
Method of viral filtration for recombinant antibody production
See Also:
A recently granted patent (Publication Number: US11919925B2) discloses a method for viral filtration involving specific steps. The method includes adjusting the pH of a fluid containing a recombinant antibody to a range between about 5.0 and 6.7, adding a stabilizing agent within a concentration of 0.1 mM to 25 mM, and passing the fluid through a pre-filter with a polyamide membrane. Subsequently, the fluid is directed through a virus filter to obtain a filtrate containing the recombinant antibody. The stabilizing agent used can be selected from a group including arginine, alanine, aspartic acid, and others. The recombinant antibody's structure is defined by specific sequences for the heavy and light chain variable regions.
Furthermore, the patent also covers variations of the method, such as the inclusion of sodium chloride in the fluid within a range of 5 mM to 300 mM, and the use of different membranes for the virus filter, including polyethersulfone, polyvinylidene fluoride (PVDF), and cuprammonium-regenerated cellulose. The pH adjustment of the fluid before the process, the specific sequences for the heavy and light chain variable regions of the recombinant antibody, and the overall filtration process are detailed in the patent claims. The method aims to provide an efficient and effective way to perform viral filtration while maintaining the stability and integrity of the recombinant antibody throughout the process.
To know more about GlobalData’s detailed insights on Alexion Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
